Ionizable cationic lipids with pKa values of 6–7 are the most effective.[53] A LNP formulation based on the ionizable lipid DLin‐MC3‐DMA (pKa = 6.44) was approved by the FDA in 2018, enclosing a therapeutic siRNA (Patisiran) for the treatment of hereditary transthyretin‐mediated amyloidosis. This evidence concerns the gene TTR and amyloidosis.